• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.

作者信息

Lee Adrian, Howell Viive M, Itchins Malinda, Wheeler Helen R, Pavlakis Nick

机构信息

Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, St Leonards, Australia; Northern Sydney Cancer Centre, Northern Sydney Local Health District, Royal North Shore Hospital, St Leonards, Australia; Sydney Medical School, Northern Clinical School, University of Sydney, Sydney, Australia.

Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital, St Leonards, Australia; Sydney Medical School, Northern Clinical School, University of Sydney, Sydney, Australia.

出版信息

Clin Lung Cancer. 2018 Sep;19(5):457-459. doi: 10.1016/j.cllc.2018.05.015. Epub 2018 Jun 5.

DOI:10.1016/j.cllc.2018.05.015
PMID:29945753
Abstract
摘要

相似文献

1
ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.ROS1重排的非小细胞肺癌、因子V莱顿突变与复发性静脉血栓形成
Clin Lung Cancer. 2018 Sep;19(5):457-459. doi: 10.1016/j.cllc.2018.05.015. Epub 2018 Jun 5.
2
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.一项多中心研究，旨在探讨 ROS1 重排非小细胞肺癌患者的血栓栓塞事件。
Lung Cancer. 2020 Apr;142:34-40. doi: 10.1016/j.lungcan.2020.01.017. Epub 2020 Jan 22.
3
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.ROS1 重排非小细胞肺癌患者中不同类型 ROS1 融合伙伴的克唑替尼疗效。
J Thorac Oncol. 2018 Jul;13(7):987-995. doi: 10.1016/j.jtho.2018.04.016. Epub 2018 Apr 25.
4
Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.验证ROS1重排在非小细胞肺癌中作为治疗靶点的作用。
J Clin Oncol. 2015 Mar 20;33(9):972-4. doi: 10.1200/JCO.2014.59.8334. Epub 2015 Feb 9.
5
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.ROS1 G2032 K 错义突变介导 ROS1 重排肺腺癌患者对 lorlatinib 的耐药，但对纳武利尤单抗联合白蛋白紫杉醇有效。
Lung Cancer. 2020 May;143:55-59. doi: 10.1016/j.lungcan.2020.03.019. Epub 2020 Mar 19.
6
Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.克唑替尼治疗后 ROS1 基因重排反复复发的非小细胞肺癌患者的完全代谢缓解。
Lung Cancer. 2013 Jul;81(1):142-3. doi: 10.1016/j.lungcan.2013.02.018. Epub 2013 Apr 1.
7
ROS1 copy number alterations are frequent in non-small cell lung cancer.ROS1基因拷贝数改变在非小细胞肺癌中很常见。
Oncotarget. 2016 Feb 16;7(7):8019-28. doi: 10.18632/oncotarget.6921.
8
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).ROS1 重排非小细胞肺癌与高静脉血栓栓塞率相关：来自 II 期、前瞻性、多中心、双臂试验（METROS）的分析。
Clin Lung Cancer. 2020 Jan;21(1):15-20. doi: 10.1016/j.cllc.2019.06.012. Epub 2019 Jun 18.
9
A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features.基于组织学特征的ROS1重排肺腺癌预测模型
PLoS One. 2016 Sep 20;11(9):e0161861. doi: 10.1371/journal.pone.0161861. eCollection 2016.
10
Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.ROS1 重排非小细胞肺癌的临床病理分析及诊断算法的提出。
J Thorac Oncol. 2013 Nov;8(11):1445-50. doi: 10.1097/JTO.0b013e3182a4dd6e.

引用本文的文献

1
High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations.不同基因组改变的非小细胞肺癌患者血栓形成事件存在高度差异。
Transl Lung Cancer Res. 2021 Mar;10(3):1512-1524. doi: 10.21037/tlcr-20-1290.
2
A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma.一种与CD74-ROS1融合共存的新型ROS1-FBXL17融合可能提高对克唑替尼的敏感性并延长肺腺癌患者的无进展生存期。
Onco Targets Ther. 2020 Nov 10;13:11499-11504. doi: 10.2147/OTT.S278907. eCollection 2020.